UNCY Unicycive Therapeutics
- 0.8800
- +0.0432+5.16%
- 0.8899
- +0.0099+1.13%
Unicycive Therapeutics News
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Benchmark: Reiterates Unicycive Therapeutics (UNCY.US) rating, adjusts Speculative Buy to Speculative Buy rating, and adjusts target price from $3.00 to $3.00.
Benchmark: Reiterates Unicycive Therapeutics (UNCY.US) rating, adjusts Speculative Buy to Speculative Buy rating, and adjusts target price from $3.00 to $3.00.
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and maintains $3 price target.
Unicycive Therapeutics: A Buy Rating on the Horizon With Promising Drug Developments and Market Potential
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDA
Unicycive Showcases Data on Kidney Disease Therapies at European Renal Congress
Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor.
Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company or
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GO
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting
– OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive
HC Wainwright & Co. : The Unicycive Therapeutics (UNCY.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $4.50.
HC Wainwright & Co. : The Unicycive Therapeutics (UNCY.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $4.50.
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Noble Financial Remains a Buy on Unicycive Therapeutics (UNCY)
Unicycive Therapeutics Q1 2024 GAAP EPS $(0.61) Misses $(0.15) Estimate
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.15) by 306.67 percent.
Unicycive Therapeutics 1Q Loss/Shr 61c >UNCY
Unicycive Therapeutics 1Q Loss/Shr 61c >UNCY
Press Release: Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
Unicycive Therapeutics | 10-Q: Quarterly report
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Benchmark: Restated Unicycive Therapeutics (UNCY.US) rating and adjusted from Speculative Buy to Specified Buy, target price of $3.00.
Benchmark Reiterates Speculative Buy on Unicycive Therapeutics, Maintains $3 Price Target
Benchmark analyst Bruce Jackson reiterates Unicycive Therapeutics with a Speculative Buy and maintains $3 price target.
Buy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial Positioning
Analysis
Price Target
No Data
